Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs MTV-273 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Jan 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2018.
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Updated cohort 3 data to be presented at the meeting.